Akari Therapeutics Plc
Research Akari Therapeutics Plc (AKTX) on Bullrun: market cap USD 15.35M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAKTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 15.35M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 4.81M
- Free cash flow-USD 3.11M
Valuation Snapshot
latest market cap is USD 15.35M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 17.30M | -USD 10.57M | n/a | 0 | USD 5.20M | USD 754.00K | USD 28.33M |
| FY2024 | USD 0 | -USD 19.80M | -USD 12.55M | n/a | 0 | USD 0 | USD 3.26M | USD 22.23M |
| FY2023 | USD 367.88K | -USD 10.01M | -USD 16.43M | n/a | 0 | USD 3.85M | n/a | -USD 229.00K |
| FY2022 | USD 607.68K | -USD 13.09M | -USD 7.63M | n/a | -0.74 | USD 654.89K | n/a | USD 1.79M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 15.35M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 13.08M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 32.44M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 17.63M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 35.01M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 71.40M | n/a | n/a | n/a |
About Akari Therapeutics Plc
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Akari Therapeutics Plc's market cap?
Akari Therapeutics Plc's market capitalization is USD 15.35M.
What does Akari Therapeutics Plc do?
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others.